The effect of formoterol over 24 h in patients with asthma: The role of enantiomers

Pulmonary Pharmacology and Therapeutics

Volumn 18, Issue 2, 2005, Pages 109-113

  Lötvall, Jan ^a   Palmqvist, Mona ^a   Ankerst, Jaro ^b   Persson, Gunnar ^b   Rosenborg, Johan ^c,e,f   Bengtsson, Thomas ^c,f   Rott, Zsuzsanna ^d   Poczi, Magdolna ^d   Devai, Ágnes ^d   Waldeck, Bertil ^c,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d Hungary ^*  (Hungary)

^e UPPSALA UNIVERSITY   (Sweden)

^f Clin Sci Astra Zeneca RandD S   (Germany)

Author keywords

Bronchodilators; Enantioselectivity; Pharmacodynamics

Indexed keywords

FORMOTEROL;

AIRWAY; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HEART RATE; HUMAN; NEBULIZER; PRIORITY JOURNAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 19944427552     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.10.007     Document Type: Article

References (23)

1. A. Greening, P. Ind, M. Northfield, and G. Shaw Added salmeterol vs. higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid Lancet 344 1994 219 224
2. R. Pauwels, C. Löfdahl, D. Postma, A. Tattersfield, P. O'Byrne, P. Barnes, and A. Ullman Effect of inhaled formoterol and budesonide on exacerbations of asthma N Engl J Med 337 1997 1405 1411
3. A. Woolcock, B. Lundback, N. Ringdal, and L. Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Crit Care Med 153 1996 1481 1488
4. K.F. Rabe, R. Jörres, D. Nowak, N. Behr, and H. Magnussen Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma Am Rev Respir Dis 147 1993 1436 1441
5. B. Waldeck Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern? J Allergy Clin Immmunol 103 1999 742 748
6. D. Handley, J. McCullough, S. Crowther, and J. Morley Sympathomimetic enantiomers and asthma Chirality 10 1998 262 272
7. D. Ormrod, and C. Spencer Levosalbutamol BioDrugs 11 1999 431 438
8. R. Ahrens, and M. Weinberger Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 108 2001 681 684
9. L. Vaickus, and R. Claus (R;R)-formoterol - rapid onset and 24 h duration of response after a single dose Am J Respir Crit Care Med 161 3 Pt 2 2000 A191
10. Anonymous American Thoracic Society: chronic bronchitis, asthma and pulmonary emphysema Am Rev Respir Dis 85 1962 762 768
11. J. Rosenborg, P. Larsson, Z. Rott, C. Böcskei, M. Poczi, and G. Juhász Relative therapeutic index between inhaled formoterol and salbutamol in asthmatic patients Respir Med 96 2002 412 417
12. M. Palmqvist, G. Persson, L. Lazer, J. Rosenborg, P. Larsson, and J. Lötvall Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 1997 2484 2489
13. J. Rosenborg, T. Bengtsson, P. Larsson, A. Blomgren, G. Persson, and J. Lötvall Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics Eur J Clin Pharmacol 56 2000 363 370
14. E. Fieller Some problems in biological assay J R Stat Soc B 16 1954 175 185
15. J.R. Fozard, and H. Buescher Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R;R)- and (S;S)-enantiomers and salmeterol in the rhesus monkey Pulm Pharmacol Ther 14 2001 289 295
16. B. Källström, J. Sjöberg, and B. Waldeck Steric aspects of formoterol and terbutaline: is there an adverse effect of the distomer on airway smooth muscle function? Chirality 8 1996 567 573
17. D. Schmidt, B. Källström, B. Waldeck, D. Branscheid, H. Magnusson, and K. Rabe The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus Naunyn-Schmiedeberg's Arch Pharmacol 361 2000 405 409
18. J. Trofast, K. Österberg, B-L. Källström, and B. Waldeck Steric aspects of agonism and antagonism at β-adrenoceptors: synthesis of and pharmacological experiments with the enantiomer of formoterol and their diastereomers Chirality 3 1991 443 450
19. D. Handley, C. Senanayake, W. Dutczak, J. Benovic, T. Walle, and R. Penn Biological actions of formoterol isomers Pulm Pharmacol Ther 15 2002 135 145
20. J. Lötvall, M. Palmqvist, P. Arvidsson, A. Maloney, P. Ventresca, and J. Ward The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients J Allergy Clin Immunol 108 2001 726 731
21. J. Ward, J. Dow, N. Dallow, P. Eynott, S. Milleri, and P. Ventresca Enantiomeric disposition of inhaled intravenous and oral racemic salbutamol in man - no evidence of enantiomeric lung metabolism Br J Clin Pharmacol 49 2000 15 22
22. J. Lecaillon, G. Kaiser, M. Palmisano, J. Morgan, and G. della Cioppa Pharmacokinetics and tolerability of formoterol in healthy volunteers after single high dose of Foradil dry powder inhalation via Aerolizer Eur J Clin Pharmacol 55 1999 131 138
23. J. Gabrielsson, W. Jusko, and L. Alari Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles Biopharm Drug Dispos 21 2000 41 52